BTAIQ — BioXcel Therapeutics Share News
0.000.00%
Last trade - 00:00- $0.53m
- $92.14m
- $0.64m
Brief: BioXcel Therapeutics: Topline Data Expected In H2 Of 2025 To Support Potential SNDA Submission For Label Expansion Of Igalmi In Home Setting
BioXcel Therapeutics Inc expected to post a loss of $6.38 a share - Earnings Preview
Brief: Bioxcel Therapeutics Announces 33% Enrollment In Serenity At-Home Pivotal Phase 3 Safety Trial
Brief: Bioxcel Therapeutics Announces Closing Of $14 Million Registered Direct Offering
Brief: BioXcel Therapeutics Provides Clinical and Business Update
Brief: BioXcel Therapeutics Increases Board Size To Eight Directors
Brief: Bioxcel Therapeutics Files For Resale Of Up To 5.1 Million Shares By The Selling Stockholders - SEC Filing
Brief: Bioxcel Therapeutics - As Of Nov 18, 431 Patent Has Been Accepted For Listing In FDA Approved Drug Products With Therapeutic Equivalence Evaluations
Brief: Bioxcel Therapeutics Announces Proposed Public Offering
BioXcel Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: BioXcel Therapeutics Q3 Basic EPS USD -0.32 Vs. IBES Estimate USD -0.54
BioXcel Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
BioXcel Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
Brief: BioXcel Therapeutics Says Phase 2A Trial Enrollment Expected In H1 2025
Brief: Bioxcel Therapeutics Plans To Reduce Workforce By 15 Employees
U.S. RESEARCH ROUNDUP-Airbnb, Dollar General, Walmart
BioXcel Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: BioXcel Therapeutics Q2 Basic EPS USD -0.21 Vs. IBES Estimate USD -0.71
BioXcel Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview